Group 1 - The company raised a total of RMB 411,999,905.24 through a non-public stock issuance of 22,562,974 shares, with a net amount of RMB 404,971,004.16 after deducting issuance costs [2][3] - As of December 31, 2024, the cumulative amount used from the raised funds was RMB 247,004,557.94, with a remaining balance of RMB 171,503,968.81 [3][4] - In the reporting period, the company used RMB 24,984,695.94 from the raised funds, resulting in a total cumulative usage of RMB 271,989,253.88 by June 30, 2025 [4][5] Group 2 - The company has established a strict management system for the raised funds, ensuring that they are stored and used according to regulations, with a revised management policy in December 2023 [5][6] - The company has signed tripartite supervision agreements with banks and sponsors to ensure proper management of the raised funds [6][7] - The company has permanently supplemented working capital with RMB 35,399,000.00 from the remaining funds of a terminated project, enhancing the efficiency of fund usage [7][16] Group 3 - The company has not changed the implementation location or method for the investment projects funded by the raised capital during the reporting period [8] - There were no idle funds temporarily used for working capital during the reporting period [10] - The company has not engaged in any illegal activities regarding the management and usage of the raised funds, ensuring compliance with all regulations [16][37]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002911 证券简称：佛燃能源 公告编号：2025-068 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司募集资金监管规则》和《深圳证券交易所上市公司自律 监管指引第1号——主板上市公司规范运作》及相关格式指引, 本公司将2025年半年度募集资金存放与使 用情况专项报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准佛山市燃气集团股份有限公司首次公开发行股票的批复》（证监 许可[2017]1921号）核准，佛山市燃气集团股份有限公司（2020年3月更名为佛燃能源集团股份有限公 司，以下简称"本公司"或"公司"）首次公开发行人民币普通股5,600万股（每股面值人民币1.00元），发 行价格为每股人民币13.94元，本次公司发行股票募集资金总额为人民币780,640,000.00元，扣除当时未 支付的保荐承销费用人民币48,725,192.45元后，实际存入募集资金账户的金额为人民币731,914,807.55 ...

Core Viewpoint - The company, Hangzhou Anxu Biotechnology Co., Ltd., has released its 2025 semi-annual report, which includes details on its financial status, operational results, and future development plans [1][7]. Group 1: Company Overview - The company is identified by the stock code 688075 and is referred to as Anxu Biotechnology [1]. - The report emphasizes the importance of reading the full semi-annual report for a comprehensive understanding of the company's performance and future plans [1]. Group 2: Financial Data - The total amount of funds raised through the public offering was RMB 1,200.30 million, with a net amount of RMB 1,055.85 million after deducting various fees [12]. - As of June 30, 2025, the balance of raised funds was RMB 27.59 million [13]. Group 3: Fund Management - The company has established a management system for the raised funds, ensuring that they are stored in designated special accounts and used according to regulations [14]. - The company has signed tripartite supervision agreements with banks to ensure proper management of the raised funds [15][16]. Group 4: Fund Usage - The company has completed several projects, reallocating surplus funds to new projects, including the "Technical R&D Headquarters Construction Project" with a planned investment of RMB 292.45 million [32][34]. - The company has not used idle raised funds to temporarily supplement working capital as of the reporting period [20]. Group 5: Compliance and Reporting - The company has complied with all relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [35].

Group 1 - The company completed a significant asset sale, divesting its solar business subsidiary, effectively optimizing its asset structure and focusing on medical information technology and services [6] - The company reported no profit distribution or capital reserve conversion during the reporting period [4] - The board of directors and supervisory board members confirmed the authenticity and completeness of the semi-annual report [1][2] Group 2 - The company raised a total of RMB 727.60 million through a non-public offering of shares, with a net amount of RMB 706.64 million after deducting issuance costs [7] - As of June 30, 2025, the company had utilized RMB 485.97 million of the raised funds, with specific projects receiving allocations [8] - The company has established a special account for managing the raised funds, ensuring compliance with regulatory requirements [9] Group 3 - The company has temporarily used idle raised funds to supplement working capital, with a balance of RMB 57.47 million remaining as of June 30, 2025 [15] - The company has also engaged in cash management of idle funds, with a total of RMB 35 million utilized for this purpose [16] - There were no instances of using excess raised funds for permanent working capital or loan repayment during the reporting period [17][18] Group 4 - The company has approved the conclusion of the "Regional Critical Illness Collaborative Rescue System Platform Construction Project," reallocating surplus funds for new projects and permanent working capital [19] - The company has adhered to regulations regarding the management and disclosure of raised funds, with no violations reported [22] Group 5 - The company announced the termination of its third employee stock ownership plan due to unfulfilled unlocking conditions, planning to repurchase 1,037,300 shares at a price of RMB 5.21 per share [26][28] - The board of directors approved the repurchase plan, ensuring it aligns with regulatory requirements and does not adversely affect the company's financial status [30][31]

Group 1 - The core viewpoint of the article is the announcement of the company's 2025 semi-annual report and related resolutions passed by the board and supervisory committee [4][59]. - The semi-annual report has been approved by the board and supervisory committee, confirming its compliance with legal and regulatory requirements [4][65]. - The company reported a total asset impairment and credit impairment provision of CNY 6,262,703.98, which will reduce the total profit for the first half of 2025 by the same amount [30][65]. Group 2 - The company conducted a non-public offering of 20,901,134 shares at a price of CNY 30.85 per share, raising a total of CNY 644,799,983.90, with a net amount of CNY 635,955,867.32 after deducting issuance costs [17]. - As of June 30, 2025, the company used CNY 10,916.01 million of the raised funds for specific projects, with no idle funds temporarily used for working capital during the first half of 2025 [24]. - The company plans to hold a temporary shareholders' meeting on September 5, 2025, to discuss various resolutions, including the approval of the semi-annual report and the proposed stock repurchase [78][79]. Group 3 - The company has approved the repurchase and cancellation of 67,800 shares of restricted stock from two former employees, which requires shareholder approval [49][69]. - The company has revised its capital structure, reducing its registered capital from CNY 236,050,695 to CNY 234,149,995 following the cancellation of repurchased shares [36][37]. - The company has established a special fund management system to ensure the proper use of raised funds, complying with relevant regulations [19][25].

Core Viewpoint - The company has conducted its semi-annual report for 2025, ensuring that all information disclosed is true, accurate, and complete, with no false records or misleading statements [1][4][10]. Group 1: Company Overview - The company is Sichuan Baili Tianheng Pharmaceutical Co., Ltd., with stock code 688506 and is listed on the Shanghai Stock Exchange [1][10]. - The company held its fourth Supervisory Board and Board meetings on August 19, 2025, to discuss and approve the semi-annual report and related matters [3][11]. Group 2: Financial Data - The company raised a total of RMB 990,470,000 from its initial public offering, with a net amount of RMB 884,397,430.28 after deducting issuance costs [29][30]. - As of June 30, 2025, the balance of the company's fundraising special account was RMB 13,164,522.54 [31]. Group 3: Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds and protect investor interests [32]. - The company has implemented special account management for the raised funds, signing relevant agreements with underwriters and banks [33]. Group 4: Fund Usage - As of June 30, 2025, the company has not used any raised funds for pre-investment or replacement [36]. - The company has temporarily used RMB 60 million of idle raised funds to supplement working capital, with a commitment to return the funds to the special account within 12 months [38].

Group 1 - The company is a high-tech innovative biopharmaceutical enterprise focusing on unmet clinical needs in oncology and autoimmune diseases, with strong R&D capabilities [1][2] - In the first half of 2025, the company achieved a net profit attributable to shareholders of -30 million yuan, a significant improvement of 88.51% compared to -262 million yuan in the same period last year [1] - The company increased its R&D investment to 450 million yuan, up 6.71% year-on-year, reflecting its commitment to new technology platform development and clinical trials [1] Group 2 - The company plans to use its own funds not exceeding 476.336 million yuan to acquire the remaining 7% equity of its subsidiary Guangzhou Nocare Pharmaceutical Technology Co., Ltd., aiming for 100% ownership [31][34] - This acquisition does not constitute a related party transaction or a major asset restructuring as defined by regulations [31][32] - The board of directors approved the acquisition without needing shareholder meeting approval, indicating a streamlined decision-making process [32][33] Group 3 - The company announced a delay in the "Information Technology Construction Project" to September 2027 and plans to inject 107 million yuan into its wholly-owned subsidiary Beijing Tianshi Pharmaceutical Technology Co., Ltd. to support project implementation [46][49] - The delay is attributed to the complexity of the project and the need for adjustments to ensure quality and effectiveness [49][54] - The company will continue to manage the raised funds strictly according to regulatory requirements, ensuring transparency and accountability [53][54] Group 4 - The company has revised and established certain internal governance systems in accordance with A-share listing rules, enhancing its governance framework [60] - The revised governance documents will be disclosed on the Shanghai Stock Exchange website, ensuring compliance and transparency [60] Group 5 - A significant shareholder, King Bridge Investments Limited, reduced its stake from 7.00% to 6.92%, which does not trigger a mandatory tender offer and does not affect the company's control structure [61][62] - The company will continue to monitor and disclose any further changes in shareholder equity as required [62]

Core Viewpoint - Jiangsu Changling Hydraulic Co., Ltd. plans to distribute a cash dividend of 4.20 yuan (including tax) for every 10 shares, based on a total share capital of 144,087,070 shares, amounting to a total cash dividend of 60,516,569.40 yuan (including tax) [11][31][32]. Company Overview - Jiangsu Changling Hydraulic Co., Ltd. is engaged in the hydraulic equipment industry, focusing on the production and development of hydraulic components [3]. Financial Data - The net profit attributable to shareholders for the first half of 2025 is reported at 65,741,689.48 yuan, with retained earnings at 607,122,441.42 yuan as of June 30, 2025 [11][32]. Dividend Distribution Plan - The company’s board of directors approved a profit distribution plan, which includes a cash dividend of 4.20 yuan per 10 shares, with no stock dividends or capital reserve transfers [11][32][31]. - The cash dividend distribution ratio for the first half of 2025 is 92.05% of the net profit attributable to shareholders [32]. Board and Supervisory Committee Meetings - The third board meeting was held on August 19, 2025, where the half-year report and profit distribution plan were approved unanimously by all attending directors [5][6][11]. - The supervisory committee also approved the half-year report and the special report on the use of raised funds, confirming compliance with relevant regulations [24][25]. Fund Management - The company has established a dedicated account for managing raised funds, ensuring compliance with regulations and protecting investor interests [14][15]. - As of June 30, 2025, the company has one dedicated fund account, with a total of 87,426.00 million yuan invested from the raised funds [22][15]. Investor Communication - An investor performance briefing is scheduled for August 29, 2025, to discuss the company's performance and address investor inquiries [39][40].

国元证券股份有限公司 关于安徽省建筑设计研究总院股份有限公司 变更部分募集资金专项账户的核查意见 国元证券股份有限公司（以下简称"国元证券"或"保荐机构"）作为安徽 省建筑设计研究总院股份有限公司（以下简称"建研设计"、"公司"）首次 公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》和《上市公司 募集资金监管规则》等相关法律、法规和规范性文件的规定，对建研设计变更 部分募集资金专项账户的事项进行了专项核查，并发表如下核查意见： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意安徽省建筑设计研究总院股份有 限公司首次公开发行股票注册的批复》（证监许可[2021]3363 号），公司首次 向社会公开发行人民币普通股（A 股）2,000.00 万股，每股发行价格为人民币 含增值税）人民币 5,866.84 万元后，公司实际募集资金净额为人民币 46,793.16 万 ...

Group 1 - The sixth meeting of the fourth supervisory board of Shaoxing Baisimei Chemical Co., Ltd. was held on August 18, 2025, with all six supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board approved the 2025 semi-annual report, stating that it accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The company strictly adhered to relevant regulations regarding the storage and use of raised funds, with all procedures followed correctly, and no violations reported [2] Group 2 - The company decided to postpone some fundraising investment projects based on the usage progress of raised funds and actual operating conditions, ensuring no change in the purpose of the funds or harm to shareholder interests [3] - The postponement of investment projects does not involve related transactions and complies with relevant laws and regulations [3]